Chee W Chia1, Juliana O Odetunde, Wook Kim, Olga D Carlson, Luigi Ferrucci, Josephine M Egan. 1. Laboratory of Clinical Investigation (C.W.C., J.O.O., O.D.C., J.M.E.) and Translational Gerontology Branch (L.F.), National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21225; and Department of Molecular Science and Technology (W.K.), Ajou University, Suwon 443-749, South Korea.
Abstract
CONTEXT: Research and clinical treatments on type 2 diabetes mainly focus on insulin deficiency with little attention paid to other islet hormones. OBJECTIVE: This study tested the hypothesis that glucose-dependent insulinotropic polypeptide (GIP) is involved in diabetes-associated multiislet hormone dysregulation. DESIGN: This paper included a case-control study involving 92 community-based volunteers from the Baltimore Longitudinal Study of Aging (BLSA): 23 with type 2 diabetes on glucose-lowering agents, 25 with newly diagnosed drug-naïve type 2 diabetes, 19 with prediabetes, and 25 with normal glucose tolerance; a separate intervention study with 13 non-BLSA volunteers with type 2 diabetes treated with diet alone, metformin, and/or metformin/sulfonylurea combination; a rodent study; and an in vitro cell line study. INTERVENTIONS: An oral glucose tolerance test was performed in the BLSA participants. For the intervention study, saline (0.9% NaCl) or synthetic human GIP (20 ng · kg(-1) · min(-1)) was administered to type 2 diabetes subjects for 180 minutes together with a meal, and plasma samples were obtained at predetermined intervals for 360 minutes. A bolus of GIP or placebo was given to C57BL/6 mice. MAIN OUTCOME MEASURES: Plasma glucose, insulin, glucagon, pancreatic polypeptide (PP), glucagon-like peptide-1 (GLP-1), and GIP were measured. RESULTS: After an oral glucose tolerance test, glucose, glucagon, PP, GLP-1, and GIP levels were significantly elevated in type 2 diabetes groups, compared with normal and prediabetes groups. GIP infusion in type 2 diabetes subjects was associated with significantly elevated PP levels compared with placebo. The GIP bolus given to C57BL/6 mice was followed by increased PP levels. GIP receptors were found in both human and mouse PP cells. CONCLUSIONS: Up-regulation of GIP production may play an important role in multihormonal dysregulation in type 2 diabetes, most likely through interaction with GIP receptors on islets.
CONTEXT: Research and clinical treatments on type 2 diabetes mainly focus on insulin deficiency with little attention paid to other islet hormones. OBJECTIVE: This study tested the hypothesis that glucose-dependent insulinotropic polypeptide (GIP) is involved in diabetes-associated multiislet hormone dysregulation. DESIGN: This paper included a case-control study involving 92 community-based volunteers from the Baltimore Longitudinal Study of Aging (BLSA): 23 with type 2 diabetes on glucose-lowering agents, 25 with newly diagnosed drug-naïve type 2 diabetes, 19 with prediabetes, and 25 with normal glucose tolerance; a separate intervention study with 13 non-BLSA volunteers with type 2 diabetes treated with diet alone, metformin, and/or metformin/sulfonylurea combination; a rodent study; and an in vitro cell line study. INTERVENTIONS: An oral glucose tolerance test was performed in the BLSA participants. For the intervention study, saline (0.9% NaCl) or synthetic humanGIP (20 ng · kg(-1) · min(-1)) was administered to type 2 diabetes subjects for 180 minutes together with a meal, and plasma samples were obtained at predetermined intervals for 360 minutes. A bolus of GIP or placebo was given to C57BL/6 mice. MAIN OUTCOME MEASURES: Plasma glucose, insulin, glucagon, pancreatic polypeptide (PP), glucagon-like peptide-1 (GLP-1), and GIP were measured. RESULTS: After an oral glucose tolerance test, glucose, glucagon, PP, GLP-1, and GIP levels were significantly elevated in type 2 diabetes groups, compared with normal and prediabetes groups. GIP infusion in type 2 diabetes subjects was associated with significantly elevated PP levels compared with placebo. The GIP bolus given to C57BL/6 mice was followed by increased PP levels. GIP receptors were found in both human and mousePP cells. CONCLUSIONS: Up-regulation of GIP production may play an important role in multihormonal dysregulation in type 2 diabetes, most likely through interaction with GIP receptors on islets.
Authors: M Nannipieri; S Baldi; A Mari; D Colligiani; D Guarino; S Camastra; E Barsotti; R Berta; D Moriconi; R Bellini; M Anselmino; E Ferrannini Journal: J Clin Endocrinol Metab Date: 2013-09-20 Impact factor: 5.958
Authors: R S Hundal; M Krssak; S Dufour; D Laurent; V Lebon; V Chandramouli; S E Inzucchi; W C Schumann; K F Petersen; B R Landau; G I Shulman Journal: Diabetes Date: 2000-12 Impact factor: 9.461
Authors: F C Brunicardi; R L Chaiken; A S Ryan; N E Seymour; J A Hoffmann; H E Lebovitz; R E Chance; R L Gingerich; D K Andersen; D Elahi Journal: J Clin Endocrinol Metab Date: 1996-10 Impact factor: 5.958
Authors: Shalea Piteau; Amy Olver; Su-Jin Kim; Kyle Winter; John Andrew Pospisilik; Francis Lynn; Susanne Manhart; Hans-Ulrich Demuth; Madeleine Speck; Raymond A Pederson; Christopher H S McIntosh Journal: Biochem Biophys Res Commun Date: 2007-08-29 Impact factor: 3.575
Authors: Chee W Chia; Olga D Carlson; Wook Kim; Yu-Kyong Shin; Cornelia P Charles; Hee Seung Kim; Denise L Melvin; Josephine M Egan Journal: Diabetes Date: 2009-03-10 Impact factor: 9.461
Authors: Chee W Chia; Michelle Shardell; Kristofer S Gravenstein; Olga D Carlson; Eleanor M Simonsick; Luigi Ferrucci; Josephine M Egan Journal: Diabetes Obes Metab Date: 2018-05-09 Impact factor: 6.577
Authors: Paul B Higgins; Robert E Shade; Irám P Rodríguez-Sánchez; Magdalena Garcia-Forey; M Elizabeth Tejero; V Saroja Voruganti; Shelley A Cole; Anthony G Comuzzie; Franco Folli Journal: Am J Physiol Endocrinol Metab Date: 2016-08-16 Impact factor: 4.310
Authors: P-L Kuo; J A Schrack; M D Shardell; M Levine; A Z Moore; Y An; P Elango; A Karikkineth; T Tanaka; R de Cabo; L M Zukley; M AlGhatrif; C W Chia; E M Simonsick; J M Egan; S M Resnick; L Ferrucci Journal: J Intern Med Date: 2020-02-27 Impact factor: 13.068
Authors: Urszula Razny; Beata Kiec-Wilk; Anna Polus; Joanna Goralska; Malgorzata Malczewska-Malec; Dominika Wnek; Anna Zdzienicka; Anna Gruca; Caroline E Childs; Maria Kapusta; Krystyna Slowinska-Solnica; Philip C Calder; Aldona Dembinska-Kiec Journal: BBA Clin Date: 2015-05-22
Authors: Sara Chowdhury; Songyan Wang; Judit Dunai; Rachel Kilpatrick; Lauren Z Oestricker; Michael J Wallendorf; Bruce W Patterson; Dominic N Reeds; Burton M Wice Journal: PLoS One Date: 2016-06-15 Impact factor: 3.240
Authors: Alison L Van Dyke; Krystle A Lang Kuhs; Meredith S Shiels; Jill Koshiol; Britton Trabert; Erikka Loftfield; Mark P Purdue; Nicolas Wentzensen; Ruth M Pfeiffer; Hormuzd A Katki; Allan Hildesheim; Troy J Kemp; Ligia A Pinto; Anil K Chaturvedi; Mahboobeh Safaeian Journal: PLoS One Date: 2017-07-28 Impact factor: 3.240
Authors: Sunghwan Suh; Mi Yeon Kim; Soo Kyoung Kim; Kyu Yeon Hur; Mi Kyoung Park; Duk Kyu Kim; Nam H Cho; Moon Kyu Lee Journal: Endocrinol Metab (Seoul) Date: 2016-03